Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Y-3 by Neurodawn Pharmaceutical for Depression: Likelihood of Approval
Y-3 is under clinical development by Neurodawn Pharmaceutical and currently in Phase II for Depression. According to GlobalData, Phase II...